Editor's Highlights—February 2026

The February issue of the IJD reflects the growing complexity of managing chronic inflammatory skin diseases in the era of targeted therapies. Covering atopic dermatitis, psoriasis, and hidradenitis suppurativa, the featured papers address clinically relevant questions related to treatment safety, disease-associated comorbidities, and long-term therapeutic outcomes. Key topics include vaccination strategies in patients receiving Janus kinase inhibitors, ocular complications associated with atopic dermatitis, malignancy considerations in biologic-treated psoriasis, long-term efficacy and safety of selective tyrosine kinase 2 (TYK2) inhibition, and dose optimization of biologic therapy in hidradenitis suppurativa. Together, these contributions highlight a shift toward personalized, risk-aware management strategies that balance sustained efficacy with long-term safety in chronic inflammatory dermatoses.